following an abbreviated submission:
fedratinib (Inrebic®) is accepted for use within NHSScotland.
Indication under review: for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.
Fedratinib provides an additional treatment choice in the therapeutic class of JAK inhibitors.
Another medicine within this therapeutic class has been accepted via the orphan medicine process.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice724KB (PDF)
Medicine details
- Medicine name:
- fedratinib (Inrebic)
- SMC ID:
- SMC2462
- Indication:
For treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are JAK inhibitor naïve or who have been treated with ruxolitinib.
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 11 April 2022